Legend Biotech Corporation (NASDAQ: LEGN) presented first-in-human clinical data for LB2102, an investigational DLL3-targeted CAR-T cell therapy for patients with relapsed or refractory small cell lung cancer and large-cell neuroendocrine carcinoma at the 2026 American Society of Clinical Oncology Annual Meeting.

The Phase 1 study enrolled 20 patients with advanced disease. LB2102 demonstrated an overall objective response rate of 20% and disease control rate of 70% across all dose levels. At higher dose levels (≥3), the therapy showed improved efficacy with an objective response rate of 28.6% and disease control rate of 78.6%. The median duration of response was 6.5 months, with ongoing responses observed in 2 patients at data cutoff.

The safety profile was manageable with no dose-limiting toxicities or treatment-related deaths reported. Cytokine release syndrome occurred in 30% of patients, all Grade 2 or lower. Immune effector cell-associated neurotoxicity syndrome occurred in 15% of patients.

LB2102 is engineered with dnTGFBR2 Armor technology designed to overcome immunosuppressive signaling within the tumor microenvironment. Legend Biotech's subsidiary entered into a license agreement with Novartis in November 2023, granting Novartis exclusive worldwide rights to develop and commercialize DLL3-targeted CAR-T therapies including LB2102.

The company also presented new analyses from the CARTITUDE program for CARVYKTI, its approved BCMA-targeted CAR-T therapy for multiple myeloma. The data showed progression-free survival and overall survival benefits across both high-risk and standard-risk cytogenetic populations, with 30-month overall survival rates greater than 85% among patients who responded to bridging therapy.

CARVYKTI is commercially available in 18 countries and has treated more than 10,000 patients to date, according to the company's press release statement.